Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..
PHARMACHOLOGIC EFFECT
Hemostatic agent used in hemophilia A. Promotes the transition of prothrombin to thrombin and the formation of a fibrin clot.
PHARMACOKINETICS
In patients with hemophilia, A T 1/2 is 12 hours.
The coagulation factor VIII activity is reduced by 15% for 12 hours.
When the temperature T 1/2 of the coagulation factor VIII increases, it may decrease.
INDICATIONS
Prevention and treatment of bleeding in hemophilia A, acquired coagulation factor deficiency VIII.
DOSING MODE
The dosage regimen is set individually at constant control of coagulation factor VIII. Enter the / in. The dose depends on the magnitude of the necessary increase in the level of activity of the coagulation factor VIII (which, in turn, is determined by the severity of the bleeding), and also on the patient's body weight.
SIDE EFFECT
Allergic reactions: chills, hives, fever; very rarely - anaphylactic reactions.
On the part of the digestive system: nausea and vomiting are possible.
Other: headache is possible.
CONTRAINDICATIONS
Hypersensitivity to coagulation factor VIII.
PREGNANCY AND LACTATION
Data on the safety of the use of coagulation factor VIII in pregnancy and during lactation are absent.
SPECIAL INSTRUCTIONS
In patients receiving coagulation factor VIII, the development of antibodies to its protein is possible. In such cases, the effectiveness of therapy is usually reduced and an increase in the dose of coagulation factor VIII may be required.
In severe hemophilia A, prophylactic use is possible.
When using drugs from human plasma or blood, the probability of infection with infectious diseases can not be completely ruled out, despite modern methods of obtaining such drugs.
DRUG INTERACTION
Danazol increases the activity of coagulation factor VIII.
